Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A's expanding LSAG portfolio may bode well for the stock, despite macroeconomic risks and stretched valuation.

Agilent Expands LSAG Segment: How Should You Approach the Stock?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems on the market to feature the new Agilent InfinityLab Assist Technology, offering enhanced, built-in system assistance capabilities. This technology allows.

Agilent Revolutionizes HPLC with the Launch of the Agilent Infinity III LC Series

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent will release financial results for the fourth quarter of fiscal year 2024 on Nov. 25.

Agilent to Announce Fourth-Quarter Fiscal Year 2024 Financial Results on Nov. 25

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will host an Analyst and Investor Day in New York City on Tuesday, Dec. 17, at 10 a.m. ET. CEO Padraig McDonnell, CFO Bob McMahon, and other senior business leaders will present information regarding Agilent's strategy, businesses, and long-term financial outlook. The event will conclude with a Q&A session. This in-person event is by invitation only, but a live webcast will be accessible through Agilent's Investor Rel.

Agilent to Host Analyst and Investor Day on Dec. 17, 2024

MIAMI--(BUSINESS WIRE)-- #Acquisition--H.I.G. Capital sold its portfolio company, BIOVECTRA Inc., to Agilent Technologies, Inc. (NYSE: A) for a purchase price of $925 million.

H.I.G. Capital Completes the Sale of BIOVECTRA

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Up 1.2% Since Last Earnings Report?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization.

Agilent Completes Acquisition of BIOVECTRA

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory tec.

Agilent Announces Cash Dividend of 23.6 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance. These credentials signify that the lab operates in accordance with CLIA regulations, which are federal standards applicable to all U.S. facilities testing human specimens for health.

Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine

Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields.

Agilent Technologies Thrives From the Forever Chemicals Crackdown

American Airlines

Boeing

General Electric

Engine repair shops have swelled to a $58 billion business, according to Alton Aviation Consultancy, and are cash cow for engine makers like GE Aerospace.

Airplane engines are in short supply. The business of fixing older ones is booming

Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Agilent (A) Reliance on International Sales: What Investors Need to Know

Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors. Recent acquisitions and divestitures show mixed results, with potential for technological enhancement but concerns about fit in the portfolio. Despite challenges in the pharma market, Agilent's diversified revenue streams and potential for growth in key areas make it a 'Buy' with a target price of $160 per share.

Agilent: A 'Buy' Due To Growing Biopharma, PFAS, And Semi

Agilent's (A) fiscal third-quarter results reflect weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.

Agilent (A) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.

These Analysts Boost Their Forecasts On Agilent After Strong Earnings

Agilent Technologies (NYSE: A ) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32.

A Stock Earnings: Agilent Technologies Beats EPS, Beats Revenue for Q3 2024

Agilent Technologies, Inc. (NYSE:A ) Q3 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Conference Call Participants Operator Ladies and gentlemen, welcome to the Agilent Technologies Q3 2024 Earnings Call. My name is Regina and I will be coordinating your call today.

Agilent Technologies, Inc. (A) Q3 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Agilent Technologies (A) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.43 per share a year ago.

Agilent Technologies (A) Q3 Earnings and Revenues Beat Estimates

Agilent Technologies on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies.

Agilent beats quarterly results on strong demand from biotech clients

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of 2023. Third-quarter GAAP net income was $282 million, or $0.97 per share. This compares with $111 million, or $0.38 per share, in the third quarter of fiscal year 2023. Non-GAAP(2) net income was $385 million, or $1.32 per share during the quarter, compared with $4.

Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results

Agilent Technologies (A) launches J&W 5Q GC/MS Columns to address the growing demand for modern laboratories.

Agilent (A) Boosts LSAG Segment With J&W 5Q GC/MS Columns

Agilent's (A) fiscal third-quarter results are likely to reflect strength in the ACG and DGG segments despite the weak LSAG segment.

Agilent (A) Set to Report Q3 Earnings: What's in the Offing?

Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2024.

Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent's industry-recognized ultra-inert performance and ultra-low-bleed techn.

News for Agilent Technologies Stock (A)